It is hard to believe they actual expect to prevent transmission of indigenous measles given that it is known to circulate and boost the immunity of the vaccinated, causing subclinical and/or mild cases among them. Whether or not subclinical and/or mild cases of measles is a good thing is arguable. - SM
http://www.medscape.com/govmt/CDC/MMWR/2000/11.00/mmwr4943.04/mmwr4943.04.html
|
From Progress Toward Interrupting Indigenous Measles Transmission - Region of
the Americas, January 1999--September 2000
[MMWR
49(43):986-990, 2000. Centers for Disease Control]
|
|
Figure 1. (click image to zoom) |
PAHO recommends a three-part vaccination strategy for
interrupting indigenous measles transmission: 1) a one-time nationwide
"catch-up" campaign targeting all persons aged 1--14 years; 2)
routine, "keep-up" vaccination among 1-year-olds; and 3) nationwide
"follow-up" campaigns conducted every 4 years, targeting all
children aged 1--4 years, regardless of previous measles vaccination status [4]. Thirty-nine (95%) of 41 countries
in the region conducted catch-up campaigns during 1989--1995 and conducted
follow-up campaigns since 1994; routine keep-up coverage in the region increased
from 80% in 1994 to 91% in 1999 [2].
From January 1999 through September 16, 2000, 28 (68%) of
41 countries in the region reported no measles cases, including Cuba, the English-speaking
Caribbean countries, and most of Central and South American countries. In
1999, 3091 confirmed cases were reported from 11 countries, 78% fewer cases
than in 1998 and 94% fewer than in 1997 (Table). In 1999,
ongoing endemic transmission occurred in four countries (Bolivia [1441
cases], Brazil [797], Argentina [313], and the Dominican Republic [274]). In
1999 and 2000, Canada, Chile, Costa Rica, Mexico, Peru, Uruguay, and the
United States reported measles importations; spread was limited by high
vaccination coverage [5--7].
From January 1 through September 16, 880 confirmed measles cases were
reported in the region, the lowest number recorded in any year during those
weeks. Endemic transmission occurred in Argentina, Bolivia, Brazil, the
Dominican Republic, and Haiti. Forty (<1%) of the approximately 12,000
reporting municipalities reported confirmed measles cases during this period.
Since December 1997, virus isolates were obtained from nine outbreaks in
the region (including urine specimens from Argentina, Bolivia, Brazil, Chile,
the Dominican Republic, Haiti, and Uruguay) and were analyzed by the measles
laboratories of the CDC and Fundação Oswaldo Cruz in Brazil. All virus were
genotype D6, which indicates its continued endemic circulation in the region.
Argentina. The 1997 measles epidemic in São Paulo,
Brazil, spread to Argentina, where 10,667 confirmed cases were reported
during 1997--1999. Of these, 10,229 (96%) occurred in 1998 and 313 (3%) in
1999. Cases decreased after a follow-up vaccination campaign was implemented
in 1998, with 98% reported measles vaccination coverage among children aged
1--4 years. From January 1 through September 16, 2000, six confirmed cases
were reported, a 99% decrease from 1999. These cases all occurred during
February 21--March 13, 2000 in the central province of Córdoba, and all but
one occurred among unvaccinated persons. Three cases occurred in young adults
and two in health-care workers.
Brazil. Following the 1997 epidemic, a national follow-up
vaccination campaign was conducted [3].
In 1999, 797 cases were reported compared with 2781 confirmed cases in 1998.
From January 1 through September 16, 47 (1%) confirmed cases were reported.
Of these, 15 (32%) were from an outbreak in the western Amazon region,
possibly related to an outbreak in Bolivia, 27 (57%) were sporadic
laboratory-confirmed cases from São Paulo, and six cases were sporadic cases
from other States. In June 2000, a national follow-up vaccination campaign
was conducted targeting children aged 1--11 years; reported nationwide
coverage was 97%.
Bolivia. In 1999, 1441 confirmed measles cases were
reported, an increase from the 1004 cases reported in 1998. A measles
epidemic began in May 1998, spreading from Yacuiba on the Argentinean border
to all regions. A follow-up vaccination campaign was conducted during
November--December 1999, with reported national coverage of 98%. However,
outbreaks continued during 2000, and house-to-house monitoring indicated that
many areas had not achieved 95% coverage during the 1999 campaign. From
January through September 16, 118 confirmed cases were reported; 110 were
associated with five outbreaks affecting rural, unvaccinated children and
young unvaccinated adults who had immigrated from rural areas. The largest
outbreak (66 cases) occurred during March--June in a Mennonite community in
Santa Cruz that objects to vaccination; this outbreak was identified after a
measles outbreak was reported from a related community in Alberta, Canada,
linked to travel to the Bolivia's Mennonite community [8]. A nationwide, house-to-house
vaccination campaign was initiated in September to administer all vaccines used
in the routine infant vaccination schedule (diphtheria and tetanus toxoids
and pertussis vaccine [DTP], measles, mumps, and rubella vaccine, and oral
poliovirus vaccine).
Dominican Republic. In 1999, 274 confirmed measles cases
were reported. From January 1 through September 16, 162 confirmed cases (18%
of the region's total) were reported. Of these, 104 (64%) occurred among
unvaccinated persons. The highest age-specific incidence rates were among
infants aged <9 months (14 cases per 100,000), children aged 9 months--4
years (five), and adults aged 20--29 years (three per 100,000).
Investigations of cases from 2000 indicated that outbreaks occurred in large
cities among young factory workers where factories that attract workers from
rural areas are located.
Haiti. No confirmed cases were reported in 1999. In 2000,
an outbreak began in Artibonite; through September 16, 351 confirmed cases
(40% of the region's total) have been reported, most from this area (241) and
metropolitan Port au Prince (72). Attack rates were highest for children aged
12--23 months (1.5 per 10,000), aged 2--4 years (1.2 per 10,000), and aged
5--9 years (0.8 per 10,000). In June, house-to-house vaccination was
initiated for all children aged 6 months--15 years.
Reported by: HS Izurieta, L Venczel, P Carrasco, G Tambini, C
Castillo, M Landaverde, M Brana, CA de Quadros, Div of Vaccines and
Immunizations, Pan American Health Organization, Washington DC. Z Garib,
Ministry of Health, C Pedreira, Pan American Health Organization, Santo Domingo,
Dominican Republic. R Quiroga, Ministry of Health, O Barrezueta, Pan American
Health Organization, La Paz, Bolivia. AM Desormeaux, Ministry of Health, F
Laender, J Dobbins, J André, Pan American Health Organization, Port au
Prince, Haiti. E Luna, L Brondi, MC Quixadá, S Parise, C Segatto, Ministry of
Health, R Prevots, Pan American Health Organization, Brasilia, Brazil. I
Micelli, J Vilosio, Ministry of Health, V Dietz, Pan American Health
Organization, Buenos Aires, Argentina. National Reference Center for Measles,
Dept of Virology, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. Respiratory
and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National
Center for Infectious Diseases; Global Measles Br, Vaccine Preventable
Disease Eradication Div, National Immunization Program, CDC.
Countries in the Region of the Americas have made
important progress in interrupting measles transmission. Countries have
dedicated health-care personnel, resources, and political support to both
vaccination programs and intensified disease surveillance. Countries that
have adequately implemented all of the PAHO-recommended strategies have
successfully interrupted measles transmission [2,4].
Effective measles control relies on achieving and sustaining a high level
of vaccine-induced measles immunity. Although Haiti and the Dominican
Republic have conducted nationwide vaccination campaigns, endemic
transmission continues, mainly because measles coverage in the campaigns did
not reach 95% [9]. Reasons
for suboptimal coverage included insufficient supervision and monitoring of
house-to-house vaccination and delayed case investigations that prevented
rapid assessment of the situation in areas with poor coverage. Sustaining a
high level of vaccine-induced immunity to prevent spread of measles from
importations is the most effective measles-control strategy.
PAHO recommends the appropriate and timely implementation of the following
strategies to achieve, maintain, and monitor the interruption of endemic
measles transmission in the region: 1) Obtaining
95%
routine coverage with measles-containing vaccine in all municipalities.
Countries should validate coverage regularly through house-to-house
monitoring and/or comparing the number of measles vaccine doses administered
to the number of first doses of DTP or the number of doses of Bacille
Calmette-Guerin vaccine; 2) Performing follow-up campaigns at least every 4
years and achieving
95%
vaccination coverage in all municipalities. Supervisors should verify the
vaccination coverage daily during the campaign through house-to-house
monitoring; 3) Vaccinating and monitoring coverage among groups at high risk
for acquiring or transmitting the disease (i.e., health-care workers, migrant
workers, groups philosophically opposed to vaccination, military recruits,
and other young adults of rural origin); 4) Conducting reliable, routine
surveillance for disease and actively validating data by looking for disease
during all house-to-house vaccinations, regular visits to schools and
health-care centers by each district's supervisor, including monthly visits
to high-risk areas (those where coverage is low, that do not submit weekly
reports, with limited access to health services, where tourism or immigration
are high, or that have had cases during the preceding weeks); and 5)
Investigating all outbreaks, including a) conducting household visits within
48 hours of identifying a suspected case and investigating all contacts and
settings where case-patients were during both their exposure periods (7--18
days preceding rash onset) and their infectious periods (from the first
respiratory symptoms until 4 days after rash onset); b) collecting blood and
either throat or nasopharyngeal swabs or urine specimens at the first contact
with the suspected case-patients, sending them to the country's measles
reference laboratory within 5 days of taking them and analyzing the serum
specimen, and reporting results within 4 days after the laboratory received
the specimen; c) identifying the epidemiological links of confirmed cases and
evaluating the risk factors involved in every outbreak; and d) verifying the
absence of measles exportations/ importations between countries within the
region, including determining the viral genotypes to identify endemic or
imported viruses.
|
|
|